Plain-English translation of NCT07560566 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a topical gel containing indomethacin can prevent a painful skin condition called hand-foot syndrome that commonly affects people taking sorafenib for advanced liver cancer. Sorafenib is a proven medication for treating advanced hepatocellular carcinoma, but about 45% of patients develop this uncomfortable side effect. The researchers hope that applying this medication directly to the skin before symptoms start might reduce or prevent the problem entirely.
Hand-foot syndrome is a frequent and painful side effect of sorafenib that can significantly reduce quality of life and sometimes force patients to stop or reduce their cancer treatment. This trial exists to see whether treating the hands and feet early with a topical anti-inflammatory gel can prevent this problem from developing in the first place.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take sorafenib by mouth twice daily at the standard dose, with adjustments as needed based on your response and side effects. At the same time, you will apply the 1% indomethacin gel to both the palms and backs of your hands twice daily for up to 12 weeks. Your doctor will monitor you closely during this time to check whether you develop hand-foot syndrome and to track any other side effects. The study will follow you for the first 12 weeks of treatment or until you develop hand-foot syndrome or stop taking sorafenib, whichever comes first.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
Taiwan